ALMS Chart
See on advanced chart >
About
Alumis Inc. was incorporated on January 29, 2021 as a Delaware corporation. They are a clinical stage biopharmaceutical company with an initial focus on developing their two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that they...
Read More
- HighlightA clinical-stage biopharmaceutical company focused on developing oral therapeutics for the treatment of immune-mediated diseases
- ExchangeNASDAQ
- Listing Date06/28/2024
- Established Date01/29/2021
- Full-time Employees107
- Address280 East Grand Avenue South San Francisco California 94080
- Tel1-650-2316625
- Website
- Fiscal Year End Date12/31
- Security TypeCommon Stock
Industry
Biotechnology